{
  "id": 1769683087151,
  "seqId": 175,
  "title": "Central Serous Chorioretinopathy (CSR) & Pachychoroid Disease Spectrum",
  "summary": "An idiopathic disorder defined by localized serous detachment of the sensory retina at the macula. This comprehensive guide covers the spectrum from acute CSR to chronic variants and Polypoidal Choroidal Vasculopathy (PCV).",
  "date": "2026-01-29T10:38:07.151Z",
  "data": {
    "title": "Central Serous Chorioretinopathy (CSR) & Pachychoroid Disease Spectrum",
    "summary": "An idiopathic disorder defined by localized serous detachment of the sensory retina at the macula. This comprehensive guide covers the spectrum from acute CSR to chronic variants and Polypoidal Choroidal Vasculopathy (PCV).",
    "summary_illustration": "<svg viewBox='0 0 100 100' xmlns='http://www.w3.org/2000/svg'><circle cx='50' cy='50' r='45' fill='none' stroke='hsl(215, 90%, 45%)' stroke-width='2'/><path d='M20 70 Q 50 40 80 70' fill='none' stroke='hsl(215, 90%, 45%)' stroke-width='4'/><path d='M20 75 Q 50 45 80 75' fill='none' stroke='hsl(215, 90%, 45%)' stroke-width='1' stroke-dasharray='2,2'/><circle cx='50' cy='45' r='3' fill='hsl(215, 90%, 45%)'/></svg>",
    "sections": [
      {
        "title": "Core Definition and Pathophysiology",
        "icon": "biotech",
        "type": "plain_text",
        "layout": "full_width",
        "color_theme": "blue",
        "content": "Central serous chorioretinopathy (CSR) is an idiopathic disorder characterized by a localized serous detachment of the sensory retina at the macula secondary to leakage from the choriocapillaris through one or more hyperpermeable RPE sites (see Fig. 14.13). CSR has been classified as one of the ‘pachychoroid’ spectrum disorders; in eyes with unilateral CSR almost two-thirds of fellow eyes have signs of pachychoroid pigment epitheliopathy."
      },
      {
        "title": "Demographics and Classification",
        "icon": "groups",
        "type": "table",
        "layout": "half_width",
        "color_theme": "purple",
        "content": {
          "headers": [
            "Category",
            "Details"
          ],
          "rows": [
            [
              "Primary Profile",
              "Typically affects one eye of a young or middle-aged White man."
            ],
            [
              "Gender Ratio",
              "Male to female ratio is 3:1; females tend to be older."
            ],
            [
              "Acute Form",
              "Self-resolving within 3–6 months."
            ],
            [
              "Chronic Form",
              "Lasting more than 12 months."
            ]
          ]
        }
      },
      {
        "title": "Genetic and Systemic Risk Factors",
        "icon": "warning",
        "type": "red_flag",
        "layout": "half_width",
        "color_theme": "red",
        "content": [
          "Corticosteroids: Use of steroids in any form (including endogenous Cushing syndrome) is significantly linked.",
          "Genetics: SNP involving the complement factor H gene on chromosome 1 predisposes to chronic form in White individuals.",
          "Helicobacter pylori infection",
          "Renal dialysis",
          "Systemic hypertension",
          "Psychological stress",
          "Pregnancy",
          "Sleep apnoea syndrome"
        ]
      },
      {
        "title": "Clinical Features: Symptoms & Signs",
        "icon": "visibility",
        "type": "key_point",
        "layout": "full_width",
        "color_theme": "green",
        "content": [
          "Symptoms: Unilateral blurring, metamorphopsia, micropsia and mild dyschromatopsia.",
          "Visual Acuity (VA): Typically 6/9–6/18; may improve with a low-strength convex lens (correcting acquired hypermetropia from retinal elevation).",
          "Choroidal thickening may be demonstrated.",
          "Round or oval detachment of the sensory retina at the macula.",
          "Subretinal fluid: Clear (early lesions) or turbid; precipitates may be present on the posterior retinal surface.",
          "RPE Changes: One or more depigmented RPE foci (often small PEDs) of variable size visible within neurosensory detachment.",
          "Atrophy/Hyperplasia: Small patches of RPE atrophy and hyperplasia elsewhere in the posterior pole (visible on FAF).",
          "Chronic Change: Substantial underlying atrophic change and gravitational tracts (fluid tracking downwards).",
          "Optic Disc Examination: Must be examined to exclude a congenital pit as the cause of neurosensory detachment."
        ]
      },
      {
        "title": "Clinical Course and Prognosis",
        "icon": "trending_up",
        "type": "chart",
        "layout": "half_width",
        "color_theme": "blue",
        "content": {
          "type": "bar",
          "data": [
            {
              "label": "Spontaneous Resolution (3-6mo)",
              "value": 80
            },
            {
              "label": "Recurrence Rate",
              "value": 50
            },
            {
              "label": "Chronic Course (>12mo)",
              "value": 15
            }
          ]
        }
      },
      {
        "title": "Memory Aid: Key Observations",
        "icon": "psychology",
        "type": "remember",
        "layout": "half_width",
        "color_theme": "yellow",
        "content": {
          "mnemonic": "STEROID",
          "explanation": "Stop Treatment (Steroids), Evaluate Resolution (3-6mo), Observe Idiopathic Detachment."
        }
      },
      {
        "title": "Investigations and Imaging Findings",
        "icon": "biotech",
        "type": "mindmap",
        "layout": "full_width",
        "color_theme": "purple",
        "content": {
          "center": "CSR Imaging",
          "branches": [
            "Amsler Grid: Confirms metamorphopsia",
            "OCT: Optically empty neurosensory elevation, RPE detachments, precipitates, thickened choroid, degenerative changes in chronic cases",
            "FA: Early hyperfluorescent spot enlarging ('ink blot') or vertical column ('smokestack'). Multiple focal leaks in chronic disease.",
            "FAF: Focal decrease at leakage/old sites; gravitational tracts visible.",
            "ICGA: Early phase shows dilated/compromised choroidal vessels; mid-stage hyperfluorescence (choroidal hyperpermeability); subclinical foci."
          ]
        }
      },
      {
        "title": "Polypoidal Choroidal Vasculopathy (PCV) Specifics",
        "icon": "emergency",
        "type": "key_point",
        "layout": "full_width",
        "color_theme": "blue",
        "content": [
          "OCTA: Shows the polyps.",
          "OCT: Multiple large pigment epithelial detachments (PEDs).",
          "Signs: ‘Double-hump’ sign and the ‘inverted V’ associated with pachychoroid.",
          "Structure: Round-oval polyps may be attached to the posterior surface of the PED.",
          "Vascularity: A branching vascular network may be seen underlying a flat PED adjacent to the polyp."
        ]
      },
      {
        "title": "Management Strategies for CSR",
        "icon": "medical_services",
        "type": "process",
        "layout": "full_width",
        "color_theme": "green",
        "content": [
          "1. Observation: Appropriate in many cases due to favorable prognosis; asymptomatic polyps may be observed.",
          "2. Discontinue Corticosteroids: Must be stopped if possible, especially in chronic, recurrent, or severe cases.",
          "3. Oral Spironolactone: 40 mg twice daily may result in faster resorption of subretinal fluid in acute CSR.",
          "4. Laser: Subthreshold (micropulse) diode laser to the RPE leakage site (less retinal damage than conventional photocoagulation).",
          "5. Photodynamic Therapy (PDT): Verteporfin at 30–50% dose/intensity; leads to complete resolution including severe chronic cases.",
          "6. Intravitreal Anti-VEGF: Commonly used with PDT; bevacizumab alone not helpful unless MNV is coexisting.",
          "7. Others: Case reports for aspirin, beta-blockers, and mifepristone (limited controlled assessment)."
        ]
      },
      {
        "title": "PCV Treatment & Combination Therapy",
        "icon": "layers",
        "type": "key_point",
        "layout": "full_width",
        "color_theme": "purple",
        "content": [
          "Combination treatment: Ranibizumab plus verteporfin PDT is superior to monotherapy for VA and polyp regression (EVEREST-II trial).",
          "Anti-VEGF: Less effective than in typical MNV, but suppresses leakage and bleeding.",
          "PDT Monotherapy: May lead to polyp regression and extended treatment effect; early PDT is better than delayed.",
          "PDT Rescue: Consider in PCV refractory to anti-VEGF monotherapy.",
          "Laser photocoagulation: Effective for feeder vessels or polyps, specifically if juxta-foveal.",
          "All treatments carry a risk of RPE tear formation (can also occur spontaneously)."
        ]
      },
      {
        "title": "Clinical Tips & Warnings",
        "icon": "lightbulb",
        "type": "remember",
        "layout": "full_width",
        "color_theme": "yellow",
        "content": {
          "mnemonic": "ICGA-PLUS",
          "explanation": "ICGA: Undertake if AMD patient doesn't respond to anti-VEGF after 3 months to check for PCV. PLUS lens: VA in acute CSR can be improved with a plus lens."
        }
      },
      {
        "title": "Rare Complications & Variants",
        "icon": "report_problem",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "red",
        "content": [
          "CMO (Cystoid Macular Oedema)",
          "MNV (Macular Neovascularization)",
          "RPE tears",
          "Bullous CSR: Characterized by large single or multiple serous retinal and RPE detachments.",
          "Photoreceptor and RPE degeneration in chronic disease (>12 months)."
        ]
      },
      {
        "title": "Visual Diagnosis Reference (Figs 14.41-14.44)",
        "icon": "image",
        "type": "plain_text",
        "layout": "full_width",
        "color_theme": "blue",
        "content": "Fig. 14.41 PCV: (A) Reddish-orange nodular terminal swellings with parapapillary leakage; (B) FA late venous phase showing hyperfluorescence; (C) Early ICGA showing polyp; (D) Late ICGA; (E) Polyp at 2 mins; (F) Polyp-like swellings with leakage at 10 mins; (G) OCT showing vascularized PEDs and pachychoroid. \nFig. 14.42 CSR: (A) Serous retinal detachment; (B) Resolving foveal CSR; (C) FAF showing subclinical lesions, RPE loss (hypoautofluorescent) and lipofuscin (hyperautofluorescent); (D) FAF gravitational tract; (E) OCT acute phase elevation.\nFig. 14.43 FA: (A-B) ‘Ink blot’ appearance; (C-D) ‘smokestack’ appearance.\nFig. 14.44 Laser: Subthreshold treatment successful results (A) before and (B) after."
      }
    ],
    "chapterId": "medical_retina"
  },
  "chapterId": "neuro",
  "_newlyImported": 1769683087151,
  "communityId": "sub_1769674938211_ebveu53zy",
  "communityAuthor": "Dodiii",
  "communityDate": "2026-01-29T08:22:18.211Z",
  "_serverSynced": true
}